The in vitro activities of the N,N-dimethylglycylamido derivatives of minocycline (DMG-MINO) and 6-demethyl-6-deoxytetracycline (DMG-DMDOT) were compared with those of minocycline, tetracycline, clindamycin, and metronidazole by using the National Committee for Clinical Laboratory Standards-approved Wadsworth agar dilution method. The MICs of DMG-MINO, DMG-DMDOT, and metronidazole at which 90% of the strains were susceptible (0.5, 1, and 1 pg/ml, respectively) were lower than those for clindamycin, minocycline, and tetracycline (4, 8, and 32 ,ug/ml, respectively 4, 8, and 16 ,ug/ml, respec-tively. DMG-MINO was more active than minocycline. The MIC of DMG-MINO at which 90% of the strains were susceptible (MIC90) was as much as 7 twofold dilutions lower than the MIC90 of minocycline (for Porphyromonas species, 0.062 and 8 jig/ml, respectively). The MIC90 of DMG-MINO for all of the anaerobes tested was 0.5 ,ug/ml, compared with 8 ,ug/ml for minocycline.
of the strains were susceptible (0.5, 1, and 1 pg/ml, respectively) were lower than those for clindamycin, minocycline, and tetracycline (4, 8 , and 32 ,ug/ml, respectively). All of the strains of anaerobes tested, except one strain of Bacteroides ovatus (MIC, 16 ,ug/ml), were susceptible to DMG-MINO and DMG-DMDOT at 8
,ug/ml.
Two new antimicrobial agents, N,N-dimethylglycylamido derivatives of minocycline (DMG-MINO) and 6-demethyl-6-deoxytetracycline (DMG-DMDOT), have been synthesized by American Cyanamid, Inc. (5) . Data from the manufacturer indicate that these compounds are active against gram-positive and gram-negative aerobic and anaerobic bacteria, including those organisms carrying the most common tetracycline resistance determinants (3, 5) . The purpose of this study was to evaluate the in vitro activities of these compounds against a large group The in vitro activities of the agents tested are listed in Table  1 . No breakpoints have been established for the new glycylcycline compounds; the National Committee for Clinical Laboratory Standards-approved breakpoints for clindamycin, tetracycline, and metronidazole are 4, 8, and 16 ,ug/ml, respectively. DMG-MINO was more active than minocycline. The MIC of DMG-MINO at which 90% of the strains were susceptible (MIC90) was as much as 7 twofold dilutions lower than the MIC90 of minocycline (for Porphyromonas species, 0.062 and 8 jig/ml, respectively). The MIC90 of DMG-MINO for all of the anaerobes tested was 0.5 ,ug/ml, compared with 8 ,ug/ml for minocycline.
DMG-DMDOT demonstrated much better activity than tetracycline against most groups of organisms. For all of the strains tested, the MIC90s of DMG-DMDOT and tetracycline were 1.0 and 32 ,ug/ml, respectively.
The two new glycylcycline compounds demonstrated excellent activity against anaerobes. DMG-MINO, DMG-DMDOT, metronidazole, and clindamycin inhibited all of the strains of Prevotella species tested at 8 ,ug/ml, compared with 82 and 64% for minocycline and tetracycline, respectively. All 9 strains of B. gracilis, 16 strains of Fusobacterium nucleatum, 12 strains of F. mortiferum-F. varium, and 30 strains of Bilophila wadsworthia tested were inhibited by all of the antimicrobial agents at 8 ,ug/ml, except for tetracycline. Ten Clostridium dificile strains were inhibited at 8 pug/ml by DMG-MINO, DMG-DMDOT, and metronidazole but only 50% were inhibited by clindamycin, minocycline, and tetracycline. All of the strains of B. ovatus tested but one (MIC, ANTIMICROB. AGENTS CHEMOTHER. 16 ug/ml) were inhibited at '8 ,ug/ml by both DMG-MINO and DMG-DMDOT. The utility of these compounds for therapy of anaerobic infections merits further investigation.
